June 21, 2022
1 min watch
Save
VIDEO: Single-agent dostarlimab 'essentially curative' for certain rectal cancer cases
In this video, Michael Cecchini, MD, discussed the late-breaking phase 2 study presented at ASCO Annual Meeting on single-agent dostarlimab for patients with mismatch repair-deficient or microsatellite instability high rectal cancer.
It was found to be "essentially curative," said Cecchini, assistant professor of medical oncology at Yale School of Medicine,of the study of 14 patients who all experienced a complete clinical response with no evidence of tumor and no need for chemoradiation or surgery. “This is very exciting.”
"I think that this validates some people's practice and will ultimately become the standard of care in the future,” Cecchini said.
Published by:
Sources/Disclosures
Collapse
Source:
Cercek A, et al. Abstract LBA5. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.
Disclosures:
Cecchini reports no relevant financial disclosures.
Read more about